Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2025-03-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于“质量回报双提升”行动方案的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the progress of their "Quality and Return Double Improvement" action plan. It includes operational highlights such as revenue, profit, R&D investment, patent applications, dividend distribution plans, employee stock ownership plan, and governance improvements. The document is relatively short (1611 characters) and reads as a progress update or corporate announcement rather than a full financial report. It does not contain detailed financial statements or comprehensive financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It also does not fit into categories like Earnings Release (ER) or Capital/Financing Update (CAP) since it is more about strategic progress and shareholder returns. The document is an announcement of progress and plans, not a full report or detailed presentation. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and corporate disclosures that do not fit other categories.
2025-03-28 Chinese
关于拟续聘2025年度审计机构的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of the audit firm for the fiscal year 2025. It details the audit firm's qualifications, independence, fees, and the approval process by the board and audit committee. It does not contain an audit report itself, nor does it include financial statements or audit results. The document is relatively short (3566 characters) and serves as a formal announcement of the intention to reappoint the auditor, pending shareholder approval. Therefore, it is not an Audit Report (AR) but an announcement related to audit matters. Given the content and length, the best fitting category is Regulatory Filings (RNS), as it is a regulatory announcement about audit firm reappointment without the actual audit report attached.
2025-03-28 Chinese
第六届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the ninth meeting of the sixth board of directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes approvals of the 2024 annual general manager work report, the 2024 board work report, the 2024 annual report and its summary, the 2024 profit distribution plan, internal control self-evaluation report, and other related reports. It also mentions that these reports will be submitted to the 2024 annual shareholders meeting for approval. The document is a formal board meeting resolution announcement, not the full annual report itself. It references the annual report and other reports being available on disclosure media but does not contain the full financial statements or detailed analysis. The document is over 5,000 characters and contains substantive content about board decisions, but it is primarily a board meeting resolution announcement. According to the filing definitions, this fits best under Board/Management Information (MANG) as it announces board meeting resolutions and management reports approvals. It is not a full Annual Report (10-K) or Audit Report (AR), nor is it a simple announcement of report publication (RPA). Therefore, the classification is MANG with high confidence.
2025-03-28 Chinese
2024年度独立董事述职报告（刘来平）
Management Reports Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance, committee participation, supervision activities, and overall evaluation for the year 2024. The content includes detailed descriptions of board meetings, audit committee activities, internal control evaluations, and governance oversight. It is not a financial report like an annual or quarterly report, nor is it an announcement or proxy statement. It is a management-related report focusing on the independent director's role and activities, which fits best under the category of Management Reports (MDA). The document length (7227 characters) and detailed content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is Management Reports (MDA).
2025-03-28 Chinese
关于开展套期保值型金融衍生品交易业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the commencement of hedging financial derivatives trading business. It details the purpose, scope, risk analysis, risk control measures, accounting treatment, and approvals related to the derivatives trading. The document is structured as a formal public announcement with no financial statements or detailed financial data. It is not a report like an annual or interim report, nor is it a call transcript or management report. It is a regulatory announcement about a new financial activity and risk management approach, including board approval details. The document length is 4287 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-28 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司2024年度募集资金存放与使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from 华英证券有限责任公司 regarding the 2024 annual verification of the storage and use of raised funds by 深圳信立泰药业股份有限公司. It includes extensive financial data on the amount of funds raised, their usage, balances, interest income, and detailed descriptions of investment projects funded by these raised funds. It also discusses compliance with regulatory requirements, changes in project implementation, and cash management of idle raised funds. The document is lengthy (over 14,000 characters) and contains substantive financial data and analysis related to the use of capital raised through a non-public stock issuance. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report, nor a certification or a general regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2025-03-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.